Report predicts drivers of $20 billion non-small cell lung cancer market growth to 2025

The non-small cell lung cancer (NSCLC) market across the eight major markets (8MM) of the USA, France, Germany, Italy, Spain, the UK, Japan, and China, will rise from $6.21 billion in 2015 to $26.71 billion by 2025, says a new report.

Research and consulting firm GlobalData's report anticipates that this rise, representing a remarkably strong compound annual growth rate of 15.7%, will be brought about by the increasing incorporation of premium-priced immune checkpoint inhibitors into the NSCLC treatment algorithm, the launch of new targeted therapies, and the rising incidence of the disease across the 8MM.

Cai Xuan, GlobalData’s analyst covering oncology, said: “In 2015, the NSCLC space was largely dominated by generic chemotherapy and targeted therapies, which accounted for around 94% of the market, while immuno-oncology sales accounted for just 6%.